## STATE OF NEW YORK

4952

2017-2018 Regular Sessions

## IN ASSEMBLY

February 6, 2017

Introduced by M. of A. ROSENTHAL -- read once and referred to the Committee on Health

AN ACT to amend the public health law, in relation to establishing a lymphedema and lymphatic diseases research grants program; and to amend the state finance law, in relation to creating the lymphedema and lymphatic diseases research and education fund

## The People of the State of New York, represented in Senate and Assembly, do enact as follows:

1	Section 1. The public health law is amended by adding a new section
2	207-a to read as follows:
3	<u>§ 207-a. Lymphedema and lymphatic diseases research grants program. 1.</u>
4	The department shall, within available appropriations, establish the
5	lymphedema and lymphatic diseases research grants program, hereafter
б	"grants program." Such grants program funds shall be used to provide
7	financial assistance in the form of grants, not to exceed fifty thousand
8	dollars per grant, to New York state biomedical research institutions
9	for working capital to further new and emerging research and development
10	for the diagnosis and treatment of lymphedema and lymphatic diseases.
11	Such grants shall be awarded on a competitive basis to biomedical
12	research institutions responding to requests for proposals issued by the
13	foundation when funds are appropriated.
14	2. (a) "Biomedical research institution" shall mean a not-for-profit
15	university, college, hospital, private or federal research laboratory
16	located in New York state, or a consortium of such entities, that
17	conducts an intensive and ongoing program of research and development
18	directly related to lymphedema and/or lymphatic diseases research.
19	(b) "Lymphedema" shall mean an accumulation of lymphatic fluid in the
20	interstitial tissue that causes swelling, most often in the arms and/or
21	legs, and occasionally in other parts of the body, from any cause.
22	(c) "Lymphatic diseases" shall include but not be limited to: insuf-
23	ficiency of lymphatic circulatory function (to include all forms of

EXPLANATION--Matter in **italics** (underscored) is new; matter in brackets [-] is old law to be omitted.

LBD05081-01-7

A. 4952

1	lymphedema), lipedema, complex congenital diseases of the lymphatic
2	vasculature, including lymphangiomatosis, lymphangioleio-myomatosis,
3	lymphangiectasias, lymphangiomas, cystic hygromas, Gorham's disease,
4	lymphangiosarcoma, and complex vascular/lymphatic malformations.
5	3. In addition to such other criteria as the department may adopt in
б	rules and regulations for the consideration of applications for grants
7	pursuant to subdivision one of this section, the foundation shall:
8	(a) determine that the applicant is unable to obtain sufficient fund-
9	ing on reasonable terms from other public or private sources to permit
10	the institution's planned investment to proceed without the required
11	assistance;
12	(b) give priority to those applications for assistance from biomedical
13	research institutions that secure private support for research or commit
14	new resources to the expansion of lymphedema and lymphatic diseases
15	research; and
16	(c) consider the potential long term economic benefits to the state of
17	awarding the specific grant and whether the grant will result in a
18	reasonable likelihood of success in meeting the purposes for which it
19	was sought by the applicant.
20	4. The department may apply to the national institutes of health, the
21	United States department of health and human services, and other appro-
22	priate federal, public, and private entities for funding. Such monies
23	shall be deposited into the lymphedema and lymphatic diseases research
24	and education fund, established pursuant to section ninety-nine-aa of
25	the state finance law.
26	5. The department shall submit to the governor, the speaker of the
27	assembly, the temporary president of the senate, and to any other state
28	legislator at his or her request, a report on the grants program by
29	September first, two thousand nineteen and annually thereafter. Such
30	report shall include, for each grant awarded, the name and location of
31	the recipient, a description of the product, device, technique, system
32	or process being researched and developed, the recipient's relationship
33	to the research institution, the amount and use of the grant, the total
34	project cost, and such other information as the department shall deem
35	appropriate. Such report shall also include a list of all applicants and
36	their contact information, regardless of receiving a grant, in order to
37	help demonstrate the need for future funds.
38	<u>6. Nothing in this section shall require the department to disclose</u>
39	any matters involving confidential intellectual property or work prod-
40	uct, whether patentable or not, including any formula, plan, pattern,
40 41	process, tool, mechanism, compound, procedure, production data or compi-
42	lation of information, which is not patented, but which is known only to
42 43	certain individuals who are using it to fabricate, produce or compound
43 44	an article of trade or service having commercial value and which gives
44 45	its user an opportunity to obtain a business advantage over competitors
46	who do not know it or use it.
40 47	§ 2. The state finance law is amended by adding a new section 99-aa to
48	read as follows:
40 49	<u>§ 99-aa. Lymphedema and lymphatic diseases research and education</u>
	fund. 1. There is hereby established in the joint custody of the commis-
50 51	sioner of taxation and finance and the comptroller, a special fund to be
51 52	known as the lymphedema and lymphatic diseases research and education
52 52	
53 E4	<u>fund, hereafter the "fund".</u> <u>2. Such fund shall consist of all monies appropriated, credited, or</u>
54 55	
55	transferred thereto from any other fund or source pursuant to law.

56 Nothing contained in this section shall prevent the state from receiving

A. 4952

1	grants, gifts or bequests for the purposes of the fund as defined in
2	this section and depositing them into the fund according to law.
3	3. Monies of the fund shall be expended only for lymphedema and lymp-
4	hatic diseases research and education projects approved by the depart-
5	ment of health.
б	4. (a) "Lymphedema" shall mean an accumulation of lymphatic fluid in
7	the interstitial tissue that causes swelling, most often in the arms
8	and/or legs, and occasionally in other parts of the body, regardless of
9	cause.
10	(b) "Lymphatic diseases" shall include but not be limited to: insuf-
11	ficiency of lymphatic circulatory function (to include all forms of
12	lymphedema), lipedema, complex congenital diseases of the lymphatic
13	vasculature, including lymphangiomatosis, lymphangioleio-myomatosis,
14	<u>lymphangiectasias, lymphangiomas, cystic hygromas, Gorham's disease,</u>
15	lymphangiosarcoma, and complex vascular/lymphatic malformations.
16	(c) "Lymphedema and lymphatic diseases research and education
17	projects" shall mean research by qualified researchers, as determined by
18	the department of health, to stimulate research on the pathogenesis and
19	new treatments for lymphedema and lymphatic diseases. Education projects
20	are those projects which promote and provide information on lymphedema
21	and lymphatic diseases including: prevention, diagnosis, treatment,
22	long-term chronic care, and/or research by qualified organizations as
23	determined by the department of health.
24	5. Monies shall be payable from the fund on the audit and warrant of
25	the comptroller on vouchers approved and certified by the commissioner
26	<u>of health.</u>
27	6. To the extent practicable, the commissioner of health shall ensure
28	that all monies received during a fiscal year are expended prior to the
29	end of that fiscal year.

30 § 3. This act shall take effect immediately.